Molecular Targeting Technologies, Inc. – Trademark Portfolio
Entity Type: 03
Molecular Targeting Technologies, Inc. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 4 filings in this category. The portfolio also extends into Class 2 (Paints) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 1 is pending. Notable registered marks include PSVUE and EBTATE. The owner is based in West Chester, PA.
833 Lincoln Ave., Unit 9
West Chester, PA 19380
Showing of trademarks Trademarks
Trademark Classifications
Molecular Targeting Technologies, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Molecular Targeting Technologies, Inc. have?
Molecular Targeting Technologies, Inc. has 7 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 pending, 1 abandoned, 3 cancelled.
What trademark classes does Molecular Targeting Technologies, Inc. file in?
Molecular Targeting Technologies, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 2 (Paints), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Molecular Targeting Technologies, Inc.'s most well-known trademarks?
Molecular Targeting Technologies, Inc.'s registered trademark portfolio includes well-known marks such as PSVUE and EBTATE. These are among 2 currently registered trademarks in the portfolio.
What is Molecular Targeting Technologies, Inc.'s trademark registration success rate?
Molecular Targeting Technologies, Inc. has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.